T HE THYROID HORMONE receptor ␤ (TR␤) is a ligand-inducible transcription factor involved in the regulation of morphogenesis and metabolism (1, 2) . The current models of thyroid hormone action suggest that in the absence of ligand the unliganded or "apo" receptor binds to specific thyroid hormone response elements (TRE) located within target gene promoters (3) (4) (5) . In this DNA-bound state, apo-TR␤ is capable of nucleating the assembly of a histone deacetylase complex, facilitating local condensation of chromatin and subsequent transcriptional silencing (6) (7) (8) (9) . Upon ligand binding, the receptor undergoes a conformational change that relieves this repressing activity by displacing the histone deacetylase complex and recruiting a complex that possesses histone acetyltransferase activity (10) (11) (12) . In this manner the repressive effects of chromatin are overcome, and transcription of the target gene ensues.
Although the components of the complexes involved in transcriptional activation and repression have been identified, and their role in TR action has been defined, little is known about the processes that lead to the exchange of complexes. It is unclear, for instance, whether the proteins involved in transcriptional activation or repression are present in different complexes within the cell or are present in a single complex whose bio-character is influenced by the state of activation of TR. The existing cofactor exchange models, which suggest that biochemically distinct activation and repression complexes exist within cells, imply that ligand-activated TR is presented constantly, with the problem of having to find appropriate cofactors before it can activate transcription. Consequently, the kinetics of target gene activation would be very sensitive to the cellular concentrations of individual components of the activation complex. If, on the other hand, the proteins required for activation and repression are present in the same complex and the role of ligand is merely to reorientate the complex, a more rapid transition to transcriptional activation could occur. Resolving this issue has important implications with respect to TR pharmacology and may help elucidate the roles of agonists and antagonists in modulating nuclear receptor action in general.
RESULTS

N-CoR Interacts Directly with ACTR
To define the biochemical processes that enable TR to function as both a transcriptional activator and a repressor, we wished to study the protein-protein interaction surfaces on the corepressor protein N-CoR which are important for its ability to modulate TR function. Using the repressor domain 3 (RD3) and the receptor interaction domain 1 (ID1) of N-CoR as tarAbbreviations: aa, Amino acid; CBP, cAMP response element binding protein-binding protein; ChIP, chromatin immunoprecipitation; CMV, cytomegalovirus; D1, type 1 iodothyronine deiodinase; ER, estrogen receptor; ␤-gal, ␤-galactosidase; GRIP-1, glucocorticoid receptor interacting protein-1; GST, glutathione-S-transferase; ID1, interaction domain 1; N-CoR, nuclear receptor corepressor; RAR, retinoic acid receptor; RD3, repressor domain 3; SMRT, silencing mediator of retinoic acid and thyroid hormone receptor; SRC1, steroid hormone receptor coactivator 1; ST3, stromelysin-3; TR␤, thyroid hormone receptor ␤; TRE, thyroid hormone response element.
gets, we performed phage display analysis to identify N-CoR-interacting peptides. The initial screen lead to the identification of N-CoR-interacting peptides, a subset of which surprisingly had similarity to the nuclear receptor coactivator, ACTR (p/CIP/AIB1/RAC3/ TRAM-1/SRC-3) (11, (13) (14) (15) (16) (17) . Although the peptides (not shown) contained relatively weak N-CoR-binding activity, their homology to ACTR intrigued us, as NCoR and ACTR are both TR cofactors, and they coexist in the same cellular compartment. This prompted us to examine a potential interaction between N-CoR and ACTR using glutathione-S-transferase (GST) pulldown experiments. As shown in Fig. 1B Direct interactions between N-CoR and ACTR were also shown to occur in intact cells (Fig. 1C) . In transfected 293T cells, we were able to demonstrate that full-length ACTR and N-CoR could be coimmunoprecipitated, using an antibody against ACTR to immunoprecipitate and a Myc antibody to detect the Myctagged N-CoR by immunoblot (Fig. 1C, lanes 1 and 2) . No signal was detected by the anti-Myc antibody in cells expressing ACTR alone (Fig. 1C, lanes 3 and 4) . The interaction between N-CoR and ACTR was also demonstrated in a reciprocal manner in which a Myctagged N-CoR fragment (N-CoR 759Ϫ2453 ) was immunoprecipitated with an anti-Myc antibody, while ACTR was detected in the immunoblots using an anti-ACTR antibody (Fig. 1D) . In addition, a significant interaction between full-length versions of ACTR and N-CoR (Gal4-ACTR and VP16-N-CoR) was observed in the mammalian two-hybrid assay ( Fig. 2A) , further supporting the hypothesis that N-CoR and ACTR interact directly in cells.
Based on the results presented thus far, it appears that a surface encompassing at least the RD3 and ID1 domains mediates the interaction between N-CoR and ACTR. Other individual N-CoR domains were not examined for their ACTR-binding ability; nevertheless, we concluded that full-length N-CoR is capable of interacting with ACTR based on results of the coimmunoprecipitation, two-hybrid, and GST pull-down assays (Figs. 1, B and C, 2A, and 3A). The results also suggest that N-CoR interacts with ACTR through surfaces distinct from those that mediate N-CoR's interaction with TR. We next evaluated the surfaces on ACTR that permit its interaction with N-CoR. Although full-length ACTR clearly associates with N-CoR in a mammalian two-hybrid assay ( Fig. 2A) , the high level of basal transcriptional activity exhibited by ACTR when tethered to DNA makes it difficult to evaluate how robust this interaction is. To circumvent this problem in the two-hybrid assays, we used ACTR 400Ϫ1000 , a fragment of the coactivator that lacks its cAMP response element binding protein-binding protein (CBP) and methyltransferase-binding sites as well as the region responsible for intrinsic histone acetyltransferase activity (11, 18) . When assayed for its interaction with VP16-N-CoR 759Ϫ2453 , the total response of Gal4-ACTR 400Ϫ1000 is equivalent to that of full-length ACTR, yet its fold of induction is much greater due to its lower basal transcriptional activity ( Fig. 2A) . To rule out the possibility that overexpression of N-CoR has a pancellular effect that might indirectly enhance activation, we performed a two-hybrid assay with N-CoR instead of VP16-N-CoR, and no enhancement of ACTR transcriptional activity was observed (Fig. 2B) . Thus, the transcriptional activity observed in the two-hybrid assays requires the presence of the VP16 domain on N-CoR and confirms that the activity observed in this assay is indeed an N-CoR-ACTR interaction.
The results of the mammalian two-hybrid assay indicate that ACTR 400Ϫ1000 contains the major N-CoR interaction surface. Also included in ACTR 400Ϫ1000 is the receptor interaction domain or RID (aa 621-821), which is responsible for mediating the coactivator's interaction with transcriptionally active nuclear receptors (11) . Consequently, we wanted to determine whether the same domain in ACTR was required for TR and N-CoR interaction. The two-hybrid assays indicated that both Gal4-ACTR 621Ϫ821 and Gal4-ACTR 400Ϫ1000 interact strongly with TR␤ ( Fig. 2C) . However, although ACTR 621Ϫ821 represents the major TR-binding surface, it is not sufficient to allow ACTR to associate with N-CoR (Fig. 2, A and B) . We have not created point mutations that split the surfaces that permit N-CoR-ACTR and N-CoR-TR interactions. However, the studies with deletion mutants indicate clearly that the surfaces within ACTR that interact with N-CoR are distinct from those required for TR binding.
Next, we wanted to determine 1) whether the nuclear corepressor SMRT (silencing mediator of retinoic acid and thyroid hormone receptors) is able to interact with ACTR, and 2) whether N-CoR and other p160 coactivators could form similar types of complexes. The GST pull-down assay shown in Fig. 3A suggests that SMRT, a corepressor protein homologous to NCoR, also has the ability to bind ACTR directly. In addition, three members of the p160 family of coactivators, ACTR, SRC-1 (steroid receptor coactivator 1), and GRIP1 (glucocorticoid receptor interacting protein 1), were found to bind N-CoR to various degrees when assayed in mammalian two-hybrid or GST pull-down assays (Fig. 3 , B and C). In these assays, ACTR appears to bind N-CoR more avidly than SRC-1. Under the conditions of our assays, GRIP1 displays little or no N-CoR-interacting activity. These results suggest that the corepressor/coactivator interaction is not limited to N-CoR and ACTR; other cofactors can also participate in this type of interaction. However, the different intrinsic abilities of p160 coactivators to interact with different corepressors (and vice versa) could determine, at least in part, the type and number
Fig. 2. ACTR Domains Interact with N-CoR
A, ACTR interacts with N-CoR in a mammalian two-hybrid assay. The interaction between the Gal4 and VP16 fusions was measured using a mammalian two-hybrid assay on a 5XGal4Luc3 reporter gene in CV1 cells. A CMV-␤-gal internal control plasmid was used to normalize the luciferase values for transfection efficiency. Protocols for transfection and the luciferase assay are described in Materials and Methods. The mean Ϯ SD are shown. B, CV1 cells were transfected with 5XGal4Luc3 reporter, CMV-␤-gal internal control vector, and plasmids as indicated. C, CV1 cells were transfected with 5XGal4Luc3 reporter, CMV-␤-gal internal control vector, and plasmids as indicated. T 3 , 10 Ϫ7 M. These results are representative of at least three independent experiments. of complexes formed between these two types of proteins.
N-CoR, ACTR, and Apo-TR Form a Trimeric Complex
Previous studies have shown that N-CoR and TR␤ form a complex in the absence of hormone (7) . In this study we have shown that both ACTR and TR interact with N-CoR, albeit using different surfaces. Cumulatively, these findings led us to hypothesize that N-CoR, ACTR, and apo-TR may form a trimeric complex in which N-CoR serves as a bridge to link ACTR and unliganded TR. This possibility was first tested in vitro using GST pull-down assays. As shown in Fig. 4A , TR␤ binds to ACTR in a T 3 -dependent manner. However, in the absence of T 3 , the addition of N-CoR also resulted in a significant ACTR/TR␤ interaction, suggesting that N-CoR can participate in a trimeric complex, possibly by functioning as a bridge between TR␤ and ACTR. In the presence of T 3 , ACTR and TR␤ directly interact, and under the conditions of this assay, the addition of N-CoR has no further potentiating effect.
Additional evidence in support of a trimeric complex was provided using a three-hybrid assay (Fig. 4B) , with which we were able to demonstrate that Gal4-ACTR and VP16-TR␤ interact in the absence of T 3 only when N-CoR, which contains both the TR and ACTR-binding regions, was coexpressed. We also demonstrated that ACTR's N-CoR-binding ability is required for ACTR to associate with unliganded TR. Specifically, ACTR 400Ϫ1000 , but not ACTR 621Ϫ821 , was able to interact with unliganded TR in the presence of N-CoR (Fig. 4B) . As we have observed previously (Fig. 2B) , Gal4-ACTR 621Ϫ821 is properly expressed in cells and displays similar TR-binding activity to ACTR 400Ϫ1000 . However, ACTR 621Ϫ821 lacks the ability to associate with N-CoR, which is probably the reason that it cannot participate in the trimeric complex. When interpreting the results of the three-hybrid assay, we also considered the minor possibility that overexpression of the corepressor protein N-CoR might indirectly affect the basal transcription level of Gal4-ACTR. This possibility seems unlikely because N-CoR had no effect in the assay where the VP16-TR␤ expression plasmid was replaced by one expressing TR alone (Fig. 4B , last lane). We conclude, therefore, that VP16-tagged TR was physically recruited to Gal4-ACTR by N-CoR.
To further demonstrate that the binding between Gal4-ACTR and apo-VP16-TR␤ depends on the bridging function of N-CoR and is not a consequence of some inherent ability of apo-VP16-TR␤ to bind Gal4-ACTR, we repeated the experiment using the TR␤ AF-2 mutant L454R. It has been shown previously that L454R is unable to interact with the p160 coactivators (19) . We also observed that L454R retains N-CoRbinding activity, but does not have the ability to bind ACTR, with or without thyroid hormone (Fig. 4C) . In our three-hybrid assay we have found that coexpression of N-CoR allows the TR mutant L454R to interact with ACTR indirectly, and that this interaction is entirely dependent on the presence of N-CoR (Fig. 4D) . Nearly identical results were obtained with another TR␤ AF2 mutant, E457K (data not shown). These findings strengthen our hypothesis that TR␤ and ACTR can interact with each other in an indirect manner in the absence of thyroid hormone by simultaneously binding to N-CoR. 35 S]methionine-labeled p160 coactivator proteins were generated using plasmids PCMX-ACTR, pCR3.1-hSRC-1, and pcDNA3-GRIP1. GST or GST-CЈN-CoR (5 g) was incubated with the 35 S-labeled p160 proteins. Input, 10%.
N-CoR and ACTR Coordinate to Regulate TR Action
It is well established that in the absence of thyroid hormone, TR/N-CoR complexes reside on TREs within target gene promoters (1, 2, 7). Our data, which identified a trimeric complex of TR/N-CoR/ACTR, implied that ACTR, via association with the TR/N-CoR complex, might also occupy TREs even in the absence of thyroid hormone. To probe this issue further we used chromatin immunoprecipitation (ChIP) assays to study the interaction of TR, N-CoR, and ACTR with the promoter regions of human type 1 iodothyronine deiodinase (D1) and human stromelysin-3 (ST3) genes, both of which contain functional TREs (20, 21) . Cross-linked chromatin was immunoprecipitated by specific antibodies and was analyzed using PCR with primers encompassing these endogenous TREs. The results of the ChIP assay suggested that in the absence of thyroid hormone, promoter regions containing TREs in both D1 and ST3 genes can be occupied by ectopically expressed TR, N-CoR, and, more interestingly, ACTR (Fig. 5A) .
We subsequently tested the hormone dependency of these factors on TREs. The results indicate that N-CoR occupies the D1 promoter in the absence of T 3 ,
Fig. 4. N-CoR, ACTR, and Apo-TR Form a Trimeric Complex
A, N-CoR promotes an ACTR/TR interaction in a GST pull-down assay. GST-ACTR 400Ϫ1000 was isolated using glutathioneconjugated Sepharose beads and was used to pull down 35 S-labeled TR␤. In vitro translated nonlabeled N-CoR 759Ϫ2453 or an equal amount of reticulocyte lysate was added to each assay. T 3 , 10 Ϫ6 M. B, N-CoR promotes ACTR/TR interaction in the mammalian two-hybrid assay. CV1 cells were transfected with 5XGal4Luc3, CMV-␤-gal, and the plasmids as indicated. pcDNA3-N-CoR or an equivalent molar amount of pcDNA3 vector was added to each assay. The results are representative of three independent assays. C, The TR AF2 mutant (L454R) does not interact with ACTR, but remains able to interact with N-CoR. CV1 cells were transfected with 5XGal4Luc3, CMV-␤-gal, and the plasmids as indicated. Twenty-four hours after transfection, cells were treated with T 3 (10 Ϫ7 M). D, N-CoR promotes ACTR/TR interaction in the mammalian two-hybrid assay. CV1 cells were transfected with 5XGal4Luc3, CMV-␤-gal, and the plasmids as indicated. pcDNA3-N-CoR or an equivalent molar amount of pcDNA3 vector was added to each assay. The results are representative of three independent assays. but not when T 3 is added (Fig. 5B) . Importantly, ACTR is able to occupy the promoter in the absence of T 3 , and the occupancy is enhanced by addition of hormone (Fig. 5C) . To confirm the specificity of the ChIP assays, we performed a parallel control assay using primers located approximately 3 kb upstream of the TRE, and we were unable to detect any significant binding to this region of the promoter (Fig. 5C) . Cumulatively, these results suggest that ACTR together with apo-TR and N-CoR can specifically occupy regions of TREs and that ACTR can reside in a protein complex at target gene promoters before ligand activation.
Our results thus far suggest that in the absence of ligand, N-CoR functions not only to suppress TRmediated gene expression, but also to raise the local concentration of ACTR, possibly to enable activated TR␤ to more efficiently activate transcription. To test this hypothesis, we performed transient transfection with a TRE-containing reporter plus plasmids expressing TR␤, ACTR, and N-CoR (Fig. 6A) . Transfected cells were grown without hormone to allow formation of the N-CoR/ACTR/TR complex. Subsequently, T 3 was added to the cells, and the TR-mediated transcriptional activity was measured after an additional period of incubation. In this cell system we observed that TR␤ was an effective activator of the TRE palindrome luciferase reporter, and that this activity was enhanced modestly when a submaximal level of ACTR was expressed ectopically. Importantly, however, coexpression of N-CoR and ACTR, but not N-CoR alone, significantly enhanced TR␤-mediated activation. The basal activity of apo-TR in the presence of ACTR and/or N-CoR was not significantly changed over that with TR alone (Fig. 6A) . Western blot analysis was used to confirm that overexpression of N-CoR does not affect the expression level of either TR␤ or ACTR (Fig. 6B ). It appears, therefore, that N-CoR increases the dynamic range of TR transcriptional activity by enhancing its ability to suppress the basal activity of TRE-containing genes in the absence of hormone (7, 9) . Yet, at the same time, it can recruit ACTR to the promoter before hormone binding to TR and thus facilitate a rapid and robust response to agonist activation.
Previous studies have shown that upon ligand activation the interaction between N-CoR and TR␤ is lost, and a strong interaction between liganded TR␤ and a coactivator ensues. Therefore, we sought to determine the effect of ligand-activated TR␤ on the interaction between ACTR and N-CoR. As shown in Fig. 6C , addition of ligand-activated TR␤ destabilized the interaction between Gal4-ACTR and VP16-NCoR 759Ϫ2453 , whereas apo-TR␤ had no effect on the corepressor/coactivator interaction (lanes 6 and 4, respectively). We propose that formation of the liganded TR␤/ACTR complex destabilizes N-CoR/ACTR interaction. Accordingly, TR mutants that cannot associate with ACTR in the presence of ligand should not be able to interfere with the N-CoR/ACTR interaction. Indeed, Fig. 6C , lane 10, shows that the mutant TR L454R cannot disrupt N-CoR/ACTR interaction upon ligand activation. Overall, our experiments with wild-type and mutant TR␤s suggest that N-CoR, ACTR, and apo-TR␤ can form a trimeric complex, with N-CoR serving as the essential bridging factor between TR and ACTR (Fig. 4) . Furthermore, upon addition of hormone, the strong and direct interaction that occurs between TR␤ and ACTR contributes to destabilization of the N-CoR/ ACTR interaction and possibly to the ejection of NCoR from the receptor/coactivator complex.
Based on our findings and those of others we have developed a schematic model to describe how the N-CoR/ACTR/TR␤ complex may be involved in the regulation of thyroid hormone action (Fig. 6D) . We A, Promoter occupancy by TR and cofactors. Cultured 293T cells were transfected with pcDNA3-TR␤, pcDNA3-ACTR, and pcDNA3-myc-N-CoR and were incubated in medium containing charcoal-stripped serum for 40 h. Soluble chromatin was prepared and immunoprecipitated with control IgG or antibodies against TR, Myc, or ACTR. Extracted DNA from the precipitated complex was subjected to PCR using primers that cover the promoter regions of the D1 and ST3 genes as indicated. B, 293T cells were transfected with pcDNA3-TR␤ and were incubated for 40 h. T 3 (10 Ϫ7 M) was applied 2 h before fixation of cells. Soluble chromatin was prepared and immunoprecipitated with anti-N-CoR (C-20). Extracted DNA from the precipitated complex was subject to PCR using primers that cover the TRE regions of the D1 genes. C, The distal region of the D1 gene promoter was examined for the presence of ACTR. Cells and soluble chromatin were prepared as described in B. Rabbit IgG or rabbit anti-ACTR was used for the immunoprecipitation. The results are representatives of at least three independent chromatin preparations and at least three PCR reactions.
propose that in the absence of thyroid hormone, TR␤ resides on a TRE within the promoter of target genes. The apo-receptor is then capable of recruiting the N-CoR/ACTR complex. Upon binding T 3 , TR␤ undergoes a conformational change that abolishes the NCoR/TR␤ interaction and favors the association of ACTR with the TR␤ coactivator-binding pocket. Thus, formation of the apo-TR␤/N-CoR/ACTR complex facilitates the localization of ACTR close to TR at TREs before ligand activation. This model suggests that the processes of activation and repression are more closely linked than originally anticipated and provides a mechanism to explain the differences in cellular responses to thyroid hormone.
DISCUSSION
The established models of TR␤ action hold that in the absence of ligand, the receptor is associated with the corepressor N-CoR (or SMRT) and its associated proteins (6, 7). This complex is capable of associating with specific thyroid hormone response elements within the regulatory regions of target genes, suppressing their basal transcriptional activity. The conformational change within TR that occurs upon ligand binding disrupts this complex, facilitating the interaction of TR with coactivators such as ACTR (11) and enabling the receptor to activate target genes. Our findings generally support this model, with the exception that we have demonstrated that the processes of TR-mediated repression and activation are both functionally and physically linked. Thus, while facilitating TR-mediated repression, the corepressor N-CoR also helps to recruit the coactivator ACTR to the apo-receptor, positioning it to respond to activating ligands.
Using a variety of different approaches, including GST pull-down, mammalian two-hybrid, and immunoprecipitation assays, we have defined a novel, direct interaction between the corepressor N-CoR and coactivator ACTR. Furthermore, we show that this corepressor-coactivator complex is associated with unliganded TR through concurrent binding of TR and ACTR to N-CoR, with N-CoR acting as a bridge be- tween the receptor and coactivator. The prerecruitment of ACTR to the apo-TR by N-CoR appears to facilitate a more robust activation of TR upon ligand treatment. Cumulatively, these experimental findings suggest that TR-mediated activation and repression are functionally and physically linked. It is likely that the amount of coupling between corepressors and coactivators and its impact on TR activity will depend on the expression levels of various cofactors and these may vary in different cell types. In support of this, we have shown that other p160 coactivators do not interact with N-CoR as well as ACTR does, while the corepressor SMRT can interact with ACTR just as well as N-CoR does. We propose, therefore, that activation and repression are integrally linked but the degree of coupling between the two processes is sensitive to alterations in the cellular expression levels of coactivators or corepressors. Accordingly, our findings may help explain the complex phenotypic differences between siblings with identical TR␤-mutations in Resistance to Thyroid Hormone syndrome (22) . It is possible that the variable penetrance of the mutant phenotype may be influenced by the relative expression of ACTR, N-CoR, and other proteins involved in formation of the N-CoR/ACTR interface.
We believe that the paradigm we suggest here, direct coupling of activation and repression, will be found to occur in other systems. In support of this hypothesis, close links between activation and repression have already been implicated in other studies. In one recent study, p300 (a coactivator) and Groucho (a corepressor) were demonstrated to bind separate domains of the transcription factor NK-4, suggesting that the coactivator, corepressor, and transcription factor may be in the same complex (23) . Likewise, N-CoR and the coactivator CBP have been shown to bind the homeobox heterodimer pbx-hox simultaneously, while protein kinase A stimulation of CBP has been found to facilitate the switch from transcriptional repression to activation in this system (24, 25) . Furthermore, a cofactor protein called SHARP was recently found to interact with both the coactivator SRA and the SMRT/ histone deacetylase corepressor complex (26) . Similar to N-CoR, SHARP is a large protein that has distinct coactivator and corepressor interacting domains. It is therefore plausible that N-CoR and SHARP are similar types of scaffolding proteins, each one interacting with and coordinating multiple coregulators of gene transcription. Such findings are consistent with our hypothesis that corepressors and coactivators coexist in a single regulatory unit.
In this study we have not addressed whether other nuclear receptors, such as retinoic acid receptor (RAR) and estrogen receptor (ER), can participate in similar partnerships with N-CoR and ACTR. RAR uses N-CoR and ACTR as coregulators like TR; therefore, it is possible that RAR integrates transcriptional repression and activation in a way similar to TR␤. Interestingly, N-CoR was recently found to be required for retinoic acid-responsive transcriptional activation of some genes (27) . Shang et al. (28) have shown that ACTR rapidly associates with ER␣ upon ligand addition, whereas other coactivators, such as CBP and pCAF, are recruited later. The importance of ACTR and NCoR in ER action is becoming more evident as several studies have shown that the relative expression levels of these two proteins may play an important role in the pathology of some ER-positive breast tumors. Specifically, a recent study by Anzick et al. (13) has shown that the level of ACTR is significantly increased in ER-positive breast cancer cells, while another study has shown that the level of N-CoR is decreased (29) . Thus, the net increase in ACTR with no repressor attached in cells might elevate the basal transcriptional activity of certain genes, which could have pathological consequences. Our study with N-CoR, ACTR, and TR␤, along with the findings of others discussed above strongly suggest that corepressors and coactivators can reside together in the same complex and that transcriptional repression and activation are more closely integrated than previously thought.
MATERIALS AND METHODS
